Related Experiment Video
Updated: Dec 31, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Autoinhibition can identify rare driver mutations and advise pharmacology
Ruth Nussinov1,2, Chung-Jung Tsai2, Hyunbum Jang2
1Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Abstract:
Identification of protein mutations that drive cancer is a major challenge. A primary reason is that driver mutations are principally identified by their high frequency even though they can also be rare. Driver mutations can locate at functional (binding or active) sites. We dub these orthosteric drivers. However, often they are allosteric drivers. Identification is particularly formidable for rare allosteric drivers. Autoinhibition, where a segment of the protein covers its functional site, is a common allosteric regulation mechanism. A modest shift in the equilibrium can switch the system from the autoinhibited to the active state. This can suggest why (i) mutations are likely to evolve to target it; (ii) inhibitors can straightforwardly relieve the autoinhibition but not vice versa; and why (iii) mutations that relieve the autoinhibition are likely to be drivers-even if they are rare. We explain in simple terms the linkage between allosteric driver mutations, release of autoinhibition, free energy landscapes, and targeted pharmacology in precision medicine. We review the literature and propose new concepts in identification of rare drivers in this framework.
Insights
Identifying rare cancer-driving mutations is challenging. This study explains how allosteric driver mutations release protein autoinhibition, aiding in their discovery for targeted precision medicine.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Identifying cancer driver mutations is crucial but challenging.
- Driver mutations are often identified by frequency, overlooking rare but significant ones.
- Allosteric driver mutations, particularly rare ones, pose a significant identification challenge.
Purpose of the Study:
- To explain the link between allosteric driver mutations and the release of protein autoinhibition.
- To propose new concepts for identifying rare driver mutations within a specific framework.
- To connect these concepts to targeted pharmacology and precision medicine.
Main Methods:
- Literature review on allosteric regulation and driver mutations.
- Conceptual framework linking autoinhibition release to driver mutation identification.
- Analysis of free energy landscapes in protein dynamics.
Main Results:
- Autoinhibition is a common regulatory mechanism targeted by mutations.
- Mutations relieving autoinhibition are likely drivers, even if rare.
- Understanding this mechanism facilitates the identification of rare allosteric drivers.
Conclusions:
- Rare allosteric driver mutations can be identified by their ability to release autoinhibition.
- This framework enhances targeted pharmacology for precision medicine.
- New strategies for discovering rare drivers can be developed based on allosteric regulation.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...